A report released today by RBC Capital about Sarepta Therapeutics (NASDAQ:SRPT) raises the target price to $108.00
- Updated: September 27, 2016
Boasting a price of $59.10, Sarepta Therapeutics (NASDAQ:SRPT) traded -0.94% lower on the day. With the last stock price close up 157.40% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SRPT has recorded a 50-day average of $32.78 and a two hundred day average of $22.96. Volume of trade was down over the average, with 3,159,114 shares of SRPT changing hands under the typical 3,971,960
In a report issued 09/28/2016 RBC Capital upped the price target of Sarepta Therapeutics (NASDAQ:SRPT) from $83.00 to $108.00 indicating a possible upside of 0.83%.
On 9/20/2016, SunTrust Banks Inc. released a statement on Sarepta Therapeutics (NASDAQ:SRPT) increased the target price from $4.00 to $48.00. At the time, this indicated a possible downside of -0.14%.
Recent Performance Chart
Sarepta Therapeutics has a 52 week low of $8.00 and a one year high of $61.60 SRPT’s total market value is presently $0.
A total of 13 equity analysts have released a ratings update on SRPT. Three brokerages rating the company a strong buy, one brokerage rating the company a buy, five brokerages rating the company a hold, four brokerages rating the company a underperform, and finally 1 broker rating the stock a sell with a consensus target price of $20.77.
General Information About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.